Genzyme Corp., of Cambridge, Mass., and partner Bayer Schering Pharma AC, of Berlin, dosed the first patient in the first of two Phase III studies comparing alemtuzumab to Rebif in multiple sclerosis patients. The randomized, rater-blinded CARE-MS I (Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis) trial is designed to compare Genzyme's monoclonal antibody to Rebif, a formulation of interferon beta-1a sold by Geneva-based Merck Serono SA, in up …
No comments:
Post a Comment